India's Ranbaxy to enter vaccines market in deal with Biovel

19 January 2010

Indian drug major Ranbaxy Laboratories, which is 64% owned by Japan's Daiichi Sankyo, has today signed an of agreements with Biovel Lifesciences based in Bangalore, India, to acquire the latter's product rights and a manufacturing facility.

The proposed transaction will give Ranbaxy access to all of Biovel's products, pipeline, intellectual property, know-how and manufacturing facility, located in Bangalore, India.

Ranbaxy had pitched in to acquire Biovel, a little-known, closely-held biotechnology company based in Bangalore, according to information that Business Line obtained from top sources in both the companies earlier this month. Biovel is engaged in developing biogenerics (patent-free biotechnology therapies) and bacterial vaccines and has the capability to do contract research, contract manufacturing and drug delivery systems, according to its web site. It has a liaison office in the USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical